NCT06130345View on ClinicalTrials.gov

Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran

CompletedOBSERVATIONAL

Enrollment

15,196,685

Participants

Timeline

Start Date

April 14, 2023

Primary Completion Date

February 29, 2024

Study Completion Date

August 31, 2024

Conditions

SARS-CoV-2

Interventions

BIOLOGICAL

SPIKEVAX

Intramuscular injection

Trial Locations (1)

10001

Aetion, Inc, New York

All Listed Sponsors

collaborator

Aetion, Inc.

OTHER

lead

ModernaTX, Inc.

INDUSTRY